Open Drug Discovery Center for Alzheimer's Disease

阿尔茨海默病开放药物发现中心

• 批准号: 10250429
• 负责人: ALLAN I LEVEY
• 金额: $ 88.81万
• 依托单位: EMORY UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-09-30 至 2024-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10250429
• 关键词: Address; Alzheimer' s Disease; Alzheimer' s disease therapeutic; Benchmarking; Bioinformatics; Biological; Biological Assay; Biomedical Research; Clinical Data; Code; Collaborations; Communities; Data; Data Analyses; Decision Making; Development; Disease; Evaluation; Genetic; Genomics; Goals; In Vitro; Investigation; Modality; Molecular; Pathway interactions; Proteins; Proteomics; Recording of previous events; Reporting; Research; Research Personnel; Research Project Grants; Resources; Review Literature; Standardization; Testing; Therapeutic; Work; base; bioinformatics tool; data reuse; drug development; drug discovery; epigenomics; innovation; interest; medical specialties; metabolomics; multiple omics; neuropathology; pre-clinical; programs; repository; tool; transcriptomics

PROJECT SUMMARY BIOINFORMATICS CORE The Open-AD Bioinformatics Core (Bioinf Core) will create scorecards to prioritize community contributed Alzheimer’s disease therapeutic hypotheses and protein targets by performing data-driven unbiased assessments of genetics, multi-omics, neuropathology, prior biological, and mechanistic evidence. After hypothesis and target prioritization, the Bioinf Core will openly distribute hypothesis and target scorecards to the research community, along with the prioritization and analysis tools and data. The overarching goals of the Bioinf Core are to establish a comparable assessment across hypotheses and targets that the Open-AD Steering Committee can use to make decisions as to whether to develop TEPs for a particular hypothesis or target; provide the community with these benchmarks for any given hypothesis that is nominated; annotate hypotheses with mechanisms that can be tested by the Assay and Screen Core; and integrate diverse and complimentary evidence in new ways to perform prioritization that will be shared with the community as new bioinformatic tools. To achieve these goals, we have assembled a team of computational researchers with complementary expertise in genetics, multi-omics, and neuropathology. The Core will be led by a team at Sage Bionetworks, a non-profit biomedical research organization, that has a history of leading innovative and collaborative research projects and has specialties in Alzheimer’s disease and multi-omic analyses.

生物信息学核心项目总结 Open-AD生物信息学核心（Bioinf Core）将创建记分卡，以优先考虑社区贡献 阿尔茨海默病治疗假说和蛋白质靶点通过执行数据驱动的无偏 遗传学、多组学、神经病理学、先前生物学和机械学证据的评估。后 假设和目标优先级，Bioinf核心将公开分发假设和目标记分卡， 研究界，沿着优先级和分析工具和数据。的总体目标 Bioinf核心是建立一个跨假设和目标的可比评估， 指导委员会可以使用它来决定是否为特定的假设制定TEP， 目标;为社区提供这些被提名的任何给定假设的基准;注释 具有可通过检测和筛选核心进行测试的机制的假设;并整合多样化和 以新的方式执行优先级排序的补充证据，将作为新的 生物信息学工具为了实现这些目标，我们组建了一个计算研究团队， 在遗传学、多组学和神经病理学方面的互补专业知识。核心将由Sage的一个团队领导 Bionetworks是一家非营利性生物医学研究组织，拥有领先的创新和 合作研究项目，并在阿尔茨海默病和多组学分析的专业。